bims-migras Biomed News
on Migrasomes
Issue of 2026–11–01
two papers selected by
Cliff Dominy



  1. Biochem Soc Trans. 2026 Oct 28. 54(10): 1513-1529
      Migrasomes are migration-dependent extracellular organelles that form on retraction fibers of migrating cells. Although they can enter the extracellular space, their biogenesis and membrane organization are distinct from those of conventional extracellular vesicle subtypes. They are involved in intercellular signaling, clearance of cellular material, and maintenance of mitochondrial homeostasis. Emerging evidence suggests their involvement in the development of kidney diseases, such as podocyte injury, membranous nephropathy, diabetic kidney disease (DKD), and renal cell carcinoma (RCC). Podocyte-derived migrasomes in urine have shown potential as non-invasive biomarkers for early detection of kidney injury, with levels correlating with PLA2R antigen expression in membranous nephropathy. In DKD, migrasomes may help mitigate oxidative stress by removing damaged mitochondria. In clear cell renal cell carcinoma, they appear to influence the tumor microenvironment, affecting disease progression and prognosis. However, research on migrasomes in kidney diseases is still in its early stages. Challenges, including an incomplete understanding of their mechanisms and a lack of standardized detection methods, limit clinical application. This review outlines recent advances in understanding migrasomes and explores their potential for early diagnosis, disease monitoring, and prognosis evaluation in kidney diseases, while discussing existing barriers to guide future research efforts.
    Keywords:  biomarkers; cell migration; molecular mechanisms; renal physiology
    DOI:  https://doi.org/10.1042/BST20260952
  2. Adv Sci (Weinh). 2026 Oct 26. pii: e78367. [Epub ahead of print]
      Excessive accumulation and insufficient clearance of apoptotic cells following spinal cord injury (SCI) are key factors contributing to persistent injury. Macrophage efferocytosis is essential for resolving injury but is compromised by mitochondrial dysfunction and lysosomal overload. Maintaining mitochondrial functional homeostasis is therefore crucial for preserving the acidic lysosomal environment, alleviating the cellular lysosomal burden, and sustaining efferocytosis. Common mitochondrial quality control (MQC) pathways such as mitophagy increase the lysosomal burden. Here, we investigated how polo-like kinase 1 (PLK1) regulates macrophage efferocytosis and elucidated the underlying mechanism of migrasome-mediated mitocytosis. We demonstrate that PLK1 regulates TSPAN4-dependent migrasome formation, which drives the selective extrusion of damaged mitochondria, alleviates the lysosomal burden, and increases efferocytic capacity. To enable targeted PLK1 delivery, we engineered macrophage membrane-coated, reactive oxygen species (ROS)-responsive nanocomplexes encapsulating PLK1 plasmids (MM-NPs@PLK1). This biomimetic nanoplatform preferentially accumulates in the injured spinal cord, promotes macrophage-associated PLK1 delivery, enhances mitocytosis and efferocytosis, supports neural tissue repair, and significantly improves locomotor recovery in SCI mice. In summary, our study reveals a PLK1-regulated MQC mechanism that sustains macrophage efferocytosis through migrasome-mediated mitocytosis, providing a promising therapeutic strategy for SCI.
    Keywords:  PLK1; functional recovery; macrophage efferocytosis; mitocytosis; spinal cord injury
    DOI:  https://doi.org/10.1002/advs.78367